Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. APYX
stocks logo

APYX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
17.50M
+23.06%
-0.060
-50%
10.23M
+8.5%
-0.120
+20%
12.41M
+9.14%
-0.100
+11.11%
Estimates Revision
The market is revising Upward the revenue expectations for Apyx Medical Corporation (APYX) for FY2025, with the revenue forecasts being adjusted by 2.38% over the past three months. During the same period, the stock price has changed by 105.61%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.38%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-16.33%
In Past 3 Month
Stock Price
Go Up
up Image
+105.61%
In Past 3 Month
Wall Street analysts forecast APYX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APYX is 6.00 USD with a low forecast of 4.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast APYX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APYX is 6.00 USD with a low forecast of 4.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.030
sliders
Low
4.00
Averages
6.00
High
8.00
Current: 4.030
sliders
Low
4.00
Averages
6.00
High
8.00
Citizens JMP
Market Perform
to
Outperform
upgrade
$8
2025-11-12
Reason
Citizens JMP
Price Target
$8
2025-11-12
upgrade
Market Perform
to
Outperform
Reason
Citizens JMP upgraded Apyx Medical to Outperform from Market Perform with an $8 price target following the Q3 report. The shares "are "inflecting" due to its latest offering, the AYON system, the analyst tells investors in a research note. The firm believes AYON, an all-in-one, single console product integrating Apyx's legacy Renuvion technology with five other surgical offerings, is positioned to benefit from its "differentiated" technological offerings, ability to streamline operating workflow, and a large and growing patient base. Citizens cites AYON's prospective appeal to physicians for the upgrade.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Apyx Medical Corp (APYX.O) is -10.89, compared to its 5-year average forward P/E of -10.24. For a more detailed relative valuation and DCF analysis to assess Apyx Medical Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.24
Current PE
-10.89
Overvalued PE
-2.43
Undervalued PE
-18.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-15.35
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-4.67
Undervalued EV/EBITDA
-26.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.46
Current PS
0.00
Overvalued PS
6.23
Undervalued PS
0.69
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

APYX News & Events

Events Timeline

(ET)
2025-12-03
08:20:00
Apyx Medical Launches Apyx One Console in South Korea
select
2025-12-01 (ET)
2025-12-01
16:10:00
Apyx Medical Files $100M Mixed Securities Shelf
select
2025-11-18 (ET)
2025-11-18
07:37:19
Apyx Medical sets price for 2.76 million shares at $3.62 in public offering with underwriters.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-03Globenewswire
Apyx Medical Launches Apyx One Console in South Korea Following Regulatory Approval
  • Market Entry: Apyx Medical Corporation has received regulatory approval from the Ministry of Food and Drug Safety in South Korea and plans to start shipping the Apyx One console and single-use handpieces in Q4 2025, marking a significant expansion in the global aesthetic surgery market.
  • Technological Innovation: The Apyx One console features an advanced 3-in-1 energy system that enables plastic surgeons to utilize Renuvion technology, enhancing surgical flexibility and efficiency, which is expected to boost the company's competitiveness in the rapidly growing South Korean aesthetic market.
  • Market Potential: The cosmetic surgery market in South Korea is projected to reach $1.7 billion in 2024 and exceed $3.9 billion by 2033, providing substantial market opportunities for Apyx Medical's products, particularly with the increasing demand for skin tightening solutions following significant weight loss.
  • Strategic Positioning: Apyx Medical's CEO highlighted that entering South Korea, known as the cosmetic surgery capital of the world, will support the company's long-term growth strategy in the Asia-Pacific region, especially as the GLP-1 weight-loss drug market rapidly expands, attracting more patients seeking body contouring solutions.
[object Object]
Preview
8.5
11-18Newsfilter
Apyx Medical Corporation Reveals $10 Million Public Offering of Common Stock Pricing

  • Public Offering Announcement: Apyx Medical Corporation has priced its underwritten public offering of 2,762,431 shares of common stock at $3.62 per share, with the offering expected to close on or about November 19, 2025.

  • Use of Proceeds: The company plans to use the net proceeds from the offering for working capital and general corporate purposes.

  • Underwriter Details: Lucid Capital Markets is the sole book-running manager for the offering, which includes a 45-day option for the underwriter to purchase an additional 414,365 shares.

  • Company Overview: Apyx Medical specializes in surgical aesthetics, offering innovative products like Renuvion and the AYON Body Contouring System, supported by extensive clinical documentation.

[object Object]
Preview
8.5
11-18Newsfilter
Apyx Medical Corporation Unveils Plans for Public Offering of Common Stock

  • Public Offering Announcement: Apyx Medical Corporation has announced the commencement of an underwritten public offering of its common stock, subject to market conditions, with no assurance on the completion or terms of the offering.

  • Role of Lucid Capital Markets: Lucid Capital Markets is serving as the sole book-running manager for the public offering, which is being made under a previously filed shelf registration statement with the SEC.

  • Company Overview: Apyx Medical specializes in surgical aesthetics, offering innovative products like Renuvion and the AYON Body Contouring System, which are designed to enhance surgical procedures and patient outcomes.

  • Forward-Looking Statements Caution: The company has issued a cautionary statement regarding forward-looking statements, highlighting various risks and uncertainties that could affect its financial performance and the success of the public offering.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Apyx Medical Corp (APYX) stock price today?

The current price of APYX is 4.03 USD — it has increased 0.75 % in the last trading day.

arrow icon

What is Apyx Medical Corp (APYX)'s business?

Apyx Medical Corporation is an advanced energy technology company. The Company's segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment's product portfolio consists of Helium Plasma Technology, which is marketed and sold as Renuvion in the cosmetic surgery market, and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment produces generators, medical devices, and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs. It specializes in the design, development, and manufacturing of electrosurgical equipment and medical devices.

arrow icon

What is the price predicton of APYX Stock?

Wall Street analysts forecast APYX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APYX is 6.00 USD with a low forecast of 4.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Apyx Medical Corp (APYX)'s revenue for the last quarter?

Apyx Medical Corp revenue for the last quarter amounts to 12.88M USD, increased 12.10 % YoY.

arrow icon

What is Apyx Medical Corp (APYX)'s earnings per share (EPS) for the last quarter?

Apyx Medical Corp. EPS for the last quarter amounts to -0.05 USD, decreased -64.29 % YoY.

arrow icon

What changes have occurred in the market's expectations for Apyx Medical Corp (APYX)'s fundamentals?

The market is revising Upward the revenue expectations for Apyx Medical Corporation (APYX) for FY2025, with the revenue forecasts being adjusted by 2.38% over the past three months. During the same period, the stock price has changed by 105.61%.
arrow icon

How many employees does Apyx Medical Corp (APYX). have?

Apyx Medical Corp (APYX) has 220 emplpoyees as of December 05 2025.

arrow icon

What is Apyx Medical Corp (APYX) market cap?

Today APYX has the market capitalization of 166.58M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free